Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients.

Learn more about:
Related Clinical Trial
Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH. Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome Exercise and Pioglitazone for HIV-Metabolic Syndromes Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected Adults Yoga for the Management of HIV-Metabolic Syndromes Pravastatin for Hyperlipidaemia in HIV. A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth Exercise for Patients With HIV Infections Lactate Metabolism Study in HIV Infected Persons Quality of Life, Sleep, and Biomarkers in People With HIV/AIDS The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells Growth Hormone Dynamics and Cardiac Steatosis in HIV The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers Detraining in People Living With HIV/AIDS SHARE: Simple HAART With Abacavir, Reyataz, and Epivir The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Metabolism and Body Shape of Healthy Children and Children With Chronic Infections Changing to Nonprotease Inhibitor Treatment to Improve Side Effects Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs White Light Scanning to Aid Body Contouring: A Pilot Project Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy The Cleveland Cardiometabolic Cohort Metabolic Abnormalities in HIV-infected Persons Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients. Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome Effects of Short-term Growth Hormone in HIV-infected Patients Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid Raltegravir Therapy for Women With HIV and Fat Accumulation The PREFORM Study: A Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring Effects of IGF-I in HIV Metabolic Disease Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy Effects of Growth Hormone Releasing Hormone in HIV A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy Body Composition and Adipose Tissue in HIV Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue CONFORM: Rotational Fractional Resection for Submental Contouring Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy TH9507 in Patients With HIV-Associated Lipodystrophy TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy Energy Expenditure of People Living With HIV/AIDS Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Egrifta Replacement and Sleep Disordered Breathing Clinical Trial to Determine the Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients Low Energy Diet and Familial Partial Lipodystrophy Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Role of the Autonomic Nervous System in HIV-Lipodystrophy Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome Therapeutic Approaches to HAART-Induced Lipodystrophy Different Surgical Modalities for Thigh Lipodystrophy Including Liposuction,Thigh Lift and Liposuction Assisted Thigh Lift Leptin to Treat Lipodystrophy Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat Corticosteroid-induced Lipodystrophy and Adipokines Short-term Effects of Leptin in People With Lipodystrophy Leptin to Treat Lipodystrophy Lipodystrophy Connect Patient Registry An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy

Brief Title

Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients.

Official Title

Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients.

Brief Summary

      This study plans to learn more about immune responses in intestinal (gut) tissue in people
      with human immunodeficiency virus (HIV) infection. This study will determine whether change
      in the composition of gut bacteria in HIV infected individuals is related to a high
      prevalence of chronic gut inflammation and metabolic disease. The investigators will also
      investigate immune-modulatory properties of specific bacteria that correlate with disease
      both by characterizing which functional genes are selected for in their genomes and by
      stimulating immune cells isolated from blood and gut tissue with bacterial isolates. This
      work will establish whether gain/loss of bacterial drivers/suppressors of information in the
      gut contributes to metabolic disease in HIV-infected individuals.
    

Detailed Description

      This is a prospective cohort and cross-sectional case-control study. Study participation will
      last up to 2 months and 93 participants will be enrolled. Participants will be evaluated for
      lipodystrophy, asked to complete food & gastrointestinal symptoms questionnaires and provide
      stool samples. A subset of participants will be asked to have a flexible sigmoidoscopy
      (mucosal biopsy).

      Cohort A will consist of 93 participants:

      Cohort A1: ART (Antiretroviral therapy) -treated HIV-infected individuals with lipodystrophy
      (n=35) Cohort A2: ART-treated HIV-infected individuals without lipodystrophy (n=18) Cohort
      A3: HIV-1 infected individuals naïve to ART (n=20) Cohort A4: HIV-1 seronegative individuals
      who are at a high risk for infection (n=20)

      Cohort B will be a selected subset of subjects from Cohort A:

      Cohort B1: ART-treated HIV-infected individuals with HIV-associated dysbiosis (n=10) Cohort
      B2: ART-treated HIV-infected individuals without HIV-associated dysbiosis (n=10)
    


Study Type

Observational


Primary Outcome

Determine the gut microbiota composition using 16S ribosomal RNA (rRNA) sequencing of fecal samples


Condition

HIV


Study Arms / Comparison Groups

 Cohort A1
Description:  ART-treated HIV-infected individuals with lipodystrophy

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

93

Start Date

November 2014

Completion Date

July 2019

Primary Completion Date

November 2018

Eligibility Criteria

        Inclusion Criteria:

          -  Men and women; 18 years to 65 years (All Cohorts)

          -  Subjects with chronic HIV-1 Infection defined as a positive ELISA confirmed by a
             positive Western Blot or plasma HIV-1 RNA level >1,000 copies/mL at any time in the
             past. (Cohorts A1, A2 & A3)

          -  HIV-1 seronegative (Cohort A4)

          -  Either with or without lipodystrophy (to be assessed at Visit 1)

          -  Body mass index (BMI) between 21-29 mg/kg2 and weight stable for at least 3 months
             (All Cohorts)

          -  Antiretroviral therapy (ART) naïve (Cohort A3): <10 days of ART treatment at any time
             prior to Visit 1 or previously on ART but off treatment for the previous 6 months
             prior to Visit 1

          -  Long-term ART (Cohort A1 & A2): Must be on same antiretroviral treatment and have a
             plasma HIV-1 RNA <25 copies/mL for 3-6 months prior to Visit 1.Liver function tests
             not greater than 2x normal, normal kidney and thyroid function. Fasting glucose must
             be <110 mg/dl

          -  Liver function tests not greater than 2x normal, normal kidney and thyroid function.
             Fasting glucose must be <110 mg/dl

          -  ART-treated individuals whose microbiota resembles those with untreated HIV infection
             and ART-treated individuals whose microbiota resembles the HIV-negative control cohort
             (equal numbers with and without lipodystrophy).(Cohort B; a subset of Cohort A)

        Exclusion Criteria:

          -  Gastrointestinal disease such as inflammatory bowel disease, Clostridium difficile
             colitis or celiac sprue.

          -  history of bowel resection, bleeding disorder, history of hyperglycemia, treated with
             high-dose glucocorticoid therapy or alpha-interferon in past year Current use of
             anticoagulant therapy

          -  Daily use of aspirin or nonsteroidal antiinflammatory drugs (NSAIDs) with inability to
             withhold drug for 7 days before and after a rectosigmoid biopsy procedure.

          -  Used antibiotics within the prior three months

          -  Pregnancy

          -  Current use of proton pump inhibitors and H2-blockers

          -  Active opportunistic or other chronic infection, such as hepatitis B or C or an active
             malignancy

          -  Patient inability to participate in the study, such as inability to undergo
             venipuncture, completion of questionnaire or mucosal biopsy (if selected) procedures
             that form part of the inclusion/exclusion criteria or part of the outcome measure.
      

Gender

All

Ages

18 Years - 65 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Catherine Lozupone, PhD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT02258685

Organization ID

14-1595


Responsible Party

Sponsor

Study Sponsor

University of Colorado, Denver


Study Sponsor

Catherine Lozupone, PhD, Principal Investigator, University of Colorado, Denver


Verification Date

December 2019